您現在所在的位置是 : 首頁-> 研發團隊
研發團隊

付學奇個人簡介 姓名 : 付學奇 性別 : 男 職稱 : 教授 是否博導 : 是 最高學曆 : 研究生 最高學位 : 博士 電話 : Email :

所在學科專業 :   生物化學與分子生物學

所研究方向 :   蛋白質酪氨酸磷酸酶和激酶的結構與功能的研究及抑製劑的篩選 ,揭示酪氨酸磷酸酶和激酶的異常與人類重大疾病的發生 、發展之間的關係 。

教育經曆 :      1979.09-1984.07吉林大學/化學/本科/學士 

                      1988.09-1991.06吉林大學/生物化學/研究生/碩士  

                      1991.09-1994.06吉林大學/化學/研究生/博士

工作經曆 :     1984.07/1988.08/吉林省中醫中藥研究院/研究實習員

                    1992.09/1997.08/吉林大學酶工程國家重點實驗室/講師

                    1994.11/1996.01/白求恩醫科大學/基礎醫學/博士後 

                    1996.01/1997.07/以色列希伯來大學/化學/博士後 

                    1997.09/2001.08/吉林大學分子生物學係/副教授

                    2001.09/2008.12/吉林大學生命科學學院/係主任/教授 

                    2009.01/現在/吉林大學生命科學學院/副院長/教授 

                    2001.04/2002.03/日本關西學院大學/生命科學/訪問學者 

                   2006.09/2007.02/美國俄克拉荷馬大學/生命科學/訪問學者 

                   2009.09/2009.12/美國俄克拉荷馬大學/生命科學/訪問學者

                   2010.11/2010.12/美國俄克拉荷馬大學/生命科學/訪問學者

工作經曆:   近5年 ,承擔10餘項科研項目 ,承擔了2項吉林大學高水平研究生課程體係建設項目。

學術論文 :   1 、期刊論文 : [1]. Wang Z, Xu B, Zhang L, Zhang J, Ma T, Zhang J, Fu X*, Tian W* ,Folic acid-functionalized mesoporous silica nanospheres hybridized with AIE luminogens for targeted cancer cell imaging, Nanoscale, 5(5), 2065-2072,2013 [2]. Cao B, Liu X, Li J, Liu S, Qi Y, Xiong Z, Zhang A, Wiese T, Fu X, Gu J, Rennie PS, Sartor O, Lee BR, Ip C, Zhao L, Zhang H, Dong Y*, 20(S)- protopanaxadiol- aglycone downregulation of the full-length and splice variants of androgen receptor, Int J Cancer, 132(6),1277-1287,2013 [3].Li Y, Deng C, Hu X, Patel B, Fu X, Qiu Y, Brand M, Zhao K, Huang S*, Dynamic interaction between TAL1 oncoprotein and LSD1 regulates TAL1 function in hematopoiesis and leukemogenesis, Oncogene, 31 (48), 5007-5008, 2012 [4]. Guo Y, Chen Y, Xu X, Fu X*, Zhao ZJ*,SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells, J Hematol Oncol, 5:72, 2012 [5]. Zhao W, Du Y, Ho WT, Fu X, Zhao ZJ*, JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines, Exp Hematol Oncol, 1(1):15,2012 [6]. Li T, Zeng L, Gao W, Cui MZ, Fu X, Xu X*, PSAP induces a unique Apaf-1 and Smac-dependent mitochondrial apoptotic pathway independent of Bcl-2 family proteins,Biochim Biophys Acta,1832(3):453-474, 2013 [7]. Yu X, Ma J, Lin F, Zhao W, Fu X, Zhao ZJ*, Myotubularin family phosphatase ceMTM3 is required for muscle maintenance by preventing excessive autophagy in Caenorhabditis elegans,BMC Cell Biol, 13:28, 2012 [8]. Yang T, Jian W, Luo Y, Fu X, Noguchi C, Bungert J, Huang S*, Qiu Y*, Acetylation of histone deacetylase 1 regulates NuRD corepressor complex activity,J Biol Chem, 287(48),40279-40291,2012 [9]. Han H, Lu L, Wang Q, Zhu M, Yuan C, Xing S*, Fu X ,Synthesis and evalsuation of oxovanadium(IV) complexes of Schiff-base condensates from 5-substituted-2-hydroxybenzaldehyde and 2-substituted-benzenamine as INVALIDive inhibitors of protein tyrosine phosphatase 1B,Dalton Trans, 41(36),11116-11124,2012 [10].Chen Y, Guo Y, Han J, Ho WT, Li S, Fu X, Zhao ZJ*,Generation and INVALIDacterization of a highly effective protein substrate for analysis of FLT3 activity,J Hematol Oncol, 5:39, 2012 [11]. Zeng L, Li T, Xu DC, Liu J, Mao G, Cui MZ, Fu X, Xu X*,Death receptor 6 induces apoptosis not through type I or type II pathways, but via a unique mitochondria-dependent pathway by interacting with Bax protein,J Biol Chem, 287(34),29125-29133,2012 [12]. Lu L, Gao X, Zhu M*, Wang S, Wu Q, Xing S*, Fu X, Liu Z, Guo M*, Exploration of biguanido-oxovanadium complexes as potent and INVALIDive inhibitors of protein tyrosine phosphatases,Biometals,25(3),599-610,2012 [13]. Qi Y, Fu X, Xiong Z, Zhang H, Hill SM, Rowan BG, Dong Y* ,Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer, PLoS One, 7(2), 2012 [14]. Wang Q, Zhu M*, Zhu R, Lu L*, Yuan C, Xing S, Fu X*, Mei Y, Hang Q,Exploration of α-aminophosphonate N-derivatives as novel, potent and INVALIDive inhibitors of protein tyrosine phosphatases, Eur J Med Chem, 49,354-364,2012 [15]. Dong B, Zhang Y, Fu X, Wang G*, Absence of JAK2V617F mutation in Chinese deep vein thrombosis patients without myeloproliferative neoplasms, Thromb Res, 129(5), 664-665,2012 [16]. Yuan C, Zhu M*, Wang Q, Lu L, Xing S, Fu X*, Jiang Z, Zhang S, Li Z, Li Z, Zhu R, Ma L, Xu L,Potent and INVALIDive inhibition of T-cell protein tyrosine phosphatase (TCPTP) by a dinuclear copper(II) complex, Chem Commun (Camb), 48(8), 1153-1155,2012 [17]. Wang Q, Zhu M*, Lu L*, Yuan C, Xing S, Fu X*, Potent inhibition of protein tyrosine phosphatases by quinquedentate binuclear copper complexes: synthesis, INVALIDacterization and biological activities, Dalton Trans,40(48),12926-12934,2011 [18]. Yu X, Zhao W, Ma J, Fu X, Zhao ZJ*, Beneficial and harmful effects of alcohol exposure on Caenorhabditis elegans worms, Biochem Biophys Res Commun, 412(4),757-762,2011 [19]. Ma L, Lu L*, Zhu M*, Wang Q, Gao F, Yuan C, Wu Y, Xing S, Fu X*, Mei Y, Gao X, Dinuclear copper complexes of organic claw: potent inhibition of protein tyrosine phosphatases,J Inorg Biochem,105(9),1138-1147,2011 [20]. Li Y, Lu L*, Zhu M*, Wang Q, Yuan C, Xing S, Fu X*, Mei Y, Potent inhibition of protein tyrosine phosphatases by copper complexes with multi- benzimidazole derivatives,Biometals,24(6),993-1004,2011 [21]. Li J, Cao B, Liu X, Fu X, Xiong Z, Chen L, Sartor O, Dong Y, Zhang H*, Berberine suppresses androgen receptor signaling in prostate cancer, Mol Cancer Ther, 10(8), 1346-1356,2011 [22]. Ma L, Lu L*, Zhu M*, Wang Q, Li Y, Xing S, Fu X*, Gao Z, Dong Y, Mononuclear copper(II) complexes with 3,5-substituted-4-salicylidene-amino-3,5- dimethyl-1,2,4-triazole: synthesis, structure and potent inhibition of protein tyrosine phosphatases, Dalton Trans, 40(24),6532-6540,2011 [23]. Ma J, Li Z, Xing S, Ho WT, Fu X*, Zhao ZJ*, Tea contains potent inhibitors of tyrosine phosphatase PTP1B, Biochem Biophys Res Commun, 407(1),98-102, 2011 [24]. Zhao W, Gao R, Lee J, Xing S, Ho WT, Fu X, Li S, Zhao ZJ*,Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory, J Hematol Oncol, 4:4,2011 [25]. Wang S, Dong H, Han J, Ho WT, Fu X, Zhao ZJ*, Identification of a variant form of tyrosine phosphatase LYP, BMC Mol Biol, 11:78,2010 [26]. Wang F, Fu X, Chen X, Chen X, Zhao Y*, Mitochondrial uncoupling inhibits p53 mitochondrial translocations in TPA-challenged skin epidermal JB6 cells, PLoS One, 5(10) ,2010 [27]. Lu L*, Wang S, Zhu M*, Liu Z, Guo M, Xing S, Fu X*, Inhibition protein tyrosine phosphatases by an oxovanadium glutamate complex, Na2[VO(Glu)2(CH3OH)](Glu = glutamate), Biometals, 23(6),1139-1147,2010 [28]. Yuan C, Lu L*, Wu Y, Liu Z, Guo M*, Xing S, Fu X*, Zhu M*,Synthesis, INVALIDacterization, and protein tyrosine phosphatases inhibition activities of oxovanadium(IV) complexes with Schiff base and polypyridyl derivatives, J InorgBiochem, 104(9), 978-986, 2010 [29]. Jiang Y, Bernard D, Yu Y, Xie Y, Zhang T, Li Y, Burnett JP, Fu X*, Wang S*, Sun D*,Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to INVALIDacterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions, J Biol Chem, 285(27),21023-21036,2010 2.會議論文 : 1. Ying Li, Xin Hu, River Ybarra1, Xueqi Fu, Yi Qiu, Keji Zhao, and Suming Huang*, Serine phosphorylation on TAL1 regulates its interaction with histone Demethylase LSD1, Journal of American Society of Hematology, 2009, Dec, Vol.114, No.22(590) ,New Orleans, 2009 2. Xin Hu, Xingguo Li, Xueqi Fu, Suming Huang*, LSD1-mediated epigenetic modification is required for TAL1 function, Florida Genetics, 2008, Oct 29-30(41), Florida, 2008

獲獎情況 :   近5年 ,培養研究生30餘名 ,其中2人獲得吉林省優秀博士論文獎 。2011年獲吉林省自然科學學術成果二等獎 ;2011年獲吉林省生物化學與分子生物學會學術創新獎 ;2010獲年吉林省科技進步一等獎 。

上一篇 :葉飛個人簡曆

下一篇: 高波個人簡介